Ginkgo Bioworks Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ginkgo Bioworks Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-7.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 53% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 64%
Sales fell 64% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-64% / -56%In 3 years sales changed by -64% while total assets changed by -56%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-7.5×Operating cash was negative last year, while some debt falls due within a year.
Higher than 56% of Healthcare companies in United States.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 71% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 72% of Healthcare companies in United States.
Tangible Net Worth Ratio
89%Of every $100 of net worth, $89 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 71% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Ginkgo Bioworks Holdings, Inc. made a loss over the last year. Ginkgo Bioworks Holdings, Inc. owes $0.58 for every $1 it owns. Ginkgo Bioworks Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGinkgo Bioworks Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.60The share price is 1.60 times Ginkgo Bioworks Holdings, Inc.'s book value per share, lower than 64% of Healthcare companies in United States.
Market cap
$673 MThe total market value of all of Ginkgo Bioworks Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$420 MWhat Ginkgo Bioworks Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.24Net worth divided by the number of shares. The share price of $9.99 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
-59.9%Ginkgo Bioworks Holdings, Inc. lost 59.9% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
Owes vs Owns
0.58×Ginkgo Bioworks Holdings, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Dividend yield
NoneGinkgo Bioworks Holdings, Inc. does not currently pay a dividend.
Revenue growth
-25%Revenue fell 25% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Profit growth
LossGinkgo Bioworks Holdings, Inc. made a loss in each of the last two years.
Profit margin
-183.8%Ginkgo Bioworks Holdings, Inc. lost $184 for every $100 of revenue.
Cash vs debt
Net debtGinkgo Bioworks Holdings, Inc. had $17 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ginkgo Bioworks Holdings, Inc.: $673 M ÷ $420 M (30 Jun 2026) = 1.6.
What is Ginkgo Bioworks Holdings, Inc.'s return on equity?
Ginkgo Bioworks Holdings, Inc. lost 59.9% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
How much does Ginkgo Bioworks Holdings, Inc. owe compared with what it owns?
Ginkgo Bioworks Holdings, Inc. owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Does Ginkgo Bioworks Holdings, Inc. pay a dividend?
No. Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend.
Is Ginkgo Bioworks Holdings, Inc.'s revenue growing?
Revenue fell 25% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.